TITLE

Bendamustine

AUTHOR(S)
Barman Balfour, J.A.; Goa, K.L.
PUB. DATE
March 2001
SOURCE
Drugs;Mar2001, Vol. 61 Issue 5, p631
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
â–´ Bendamustine is a bifunctional alkylating agent with cytotoxic activity against human ovarian and breast cancers in vitro. It shows only partial in vitro cross-resistance with cyclophosphamide, melphalan, carmustine and cisplatin. â–´ Bendamustine as monotherapy or as part of combination chemotherapy protocols for first-line or subsequent treatment produced objective response rates of 61 to 97% in patients with Hodgkin's disease or non-Hodgkin's lymphoma (NHL) [41 to 48% in high grade NHL]. â–´ In patients with multiple myeloma, a bendamustine/ prednisone regimen produced a higher rate of complete response (32 vs 11%) and more durable responses than a melphalan/prednisone regimen. â–´ Substitution of bendamustine for cyclophosphamide in a standard first-line COP regimen (cyclophosphamide, vincristine and prednisolone) yielded similar response rates in patients with advanced low grade NHL. â–´ Substituting bendamustine for cyclophosphamide in the CMF protocol (cyclophosphamide, methotrexate and fluorouracil) prolonged remission from 6.2 to 15.2 months in patients with metastatic breast cancer. â–´ The most common adverse events in patients receiving bendamustine are haematological events and gastrointestinal disturbances. Bendamustine has a relatively low propensity to induce alopecia.
ACCESSION #
4386941

 

Related Articles

  • Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Glaspy, J.A.; Jadeja, J.S.; Justice, G.; Kessler, J.; Richards, D.; Schwartzberg, L.; Tchekmedyian, N.S.; Armstrong, S.; O'Byrne, J.; Rossi, G.; Colowick, A.B. // British Journal of Cancer;7/29/2002, Vol. 87 Issue 3, p268 

    Assesses the safety of darbepoetin alfa in patients receiving cancer chemotherapy. Feasibility of administering darbopoetin every versus every two weeks; Drug dosage; Dose-response relationships.

  • Preface [Hot topic: Anti-Cancer Drugs (Executive Editor : Elke Bergmann-Leitner)]. Bergmann-Leitner, Elke // Current Pharmaceutical Design;Oct2003, Vol. 9 Issue 25, p1 

    Despite decades of intensive research there have only been a limited number of small success stories in the area of cancer treatment. This issue of Current Pharmaceutical Design features several novel approaches in the development of anti-cancer treatments. Cancer, being one of the leading...

  • Combinations of targeted therapies take aim at multiple pathways. Goldman, Bruce // JNCI: Journal of the National Cancer Institute;11/19/2003, Vol. 95 Issue 22, p1656 

    Part I. Focuses on the use of novel targeted drugs in the treatment of cancer. Differences of the drugs with existing products; Targeted drugs from various companies; Mechanism of action; Combination trials of targeted therapies.

  • Demand grows for early access to promising cancer drugs. Baldwin, Joyce // JNCI: Journal of the National Cancer Institute;11/20/2002, Vol. 94 Issue 22, p1668 

    Discusses the influence of expanded access programs in cancer patients' access to investigational drugs in the U.S. Patients' receipt of investigational drugs earlier than phase III of the clinical trial process; Patient advocacy groups' role in the growth of expanded access programs; Factors...

  • CME Questions.  // Clinical Oncology Alert;May2007, Vol. 23 Issue 5, p39 

    A quiz concerning the drugs for the treatment of cancer is presented.

  • Vandetanib Tablets (Zactima). Elliott, William T.; Chan, James // Internal Medicine Alert;5/15/2011, Vol. 33 Issue 9, p69 

    The article offers information on the effectiveness of Vandetanib tablets, marketed under the brand name Zactima from the company AstraZeneca, in treating patients with medullary thyroid cancer (MTC).

  • CME Question.  // Clinical Oncology Alert;Dec2009, Vol. 25 Issue 12, p96 

    A quiz related to cancer treatment and anticancer drugs is presented.

  • Targeted therapy pans out for treating cancer. McCann, Jean // Drug Topics;7/21/2003, Vol. 147 Issue 14, DRUG TOPICS FOR THE... p17 

    Focuses on clinical studies of targeted therapy for cancer, presented at the 39th annual meeting of the American Society of Clinical Oncology. Effectiveness of antiangiogenesis drugs in extending survival of patients with advanced cancer; Combination treatment for cancer; Phase III studies of...

  • Reply to: Gilligan T. Is There Such a Thing as Cancer Treatment That Isn't Worth Its Cost? The Oncologist 2012;17:3-4. Graham, Donna Marie; O'Reilly, Seamus // Oncologist;Jan2013, Vol. 18 Issue 1, pe1 

    Methods to reduce the costs of anticancer drugs are proposed.

  • Concern over access to new anticancer drugs in Quebec.  // PharmacoEconomics & Outcomes News;11/2/2013, Issue 690, p3 

    The article reports on the concerns of the Coalition Priorité Cancer au Québec over the access to new anticancer drugs in the Canadian province.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics